GBT is a healthcare company focusing on discovering, developing, and delivering innovative treatments for underserved patient communities. Their lead product candidate, voxelotor, is an oral, once-daily therapy being developed to treat sickle cell disease. As a clinical-stage biopharmaceutical firm, GBT commits to providing hope to those in need through novel treatments.
Founded in South San Francisco, California, GBT is led by CEO Ted W. Love and has grown into a medium-sized company with 457 employees and an annual revenue of $194.7 million. The organization's mission centers around life-changing treatments for those suffering from grievous blood-based disorders, starting with the crucial battle against sickle cell disease.
